ICH E6 places a strong emphasis on informed consent, requiring that participants are fully aware of the potential risks and benefits involved in the clinical trial. It also mandates rigorous monitoring and auditing procedures to ensure that any adverse events are promptly identified and addressed. These measures are particularly important in cancer trials, where patients may already be in a vulnerable state.